Wall Street brokerages expect Galena Biopharma Inc (NASDAQ:GALE) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galena Biopharma’s earnings. Galena Biopharma reported earnings of $1.20 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 112.5%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Galena Biopharma will report full year earnings of ($0.56) per share for the current year. For the next year, analysts expect that the business will report earnings of ($0.86) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Galena Biopharma.

Galena Biopharma (NASDAQ:GALE) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. During the same quarter last year, the company posted ($0.07) EPS.

Several equities research analysts recently issued reports on GALE shares. Zacks Investment Research raised shares of Galena Biopharma from a “hold” rating to a “strong-buy” rating and set a $0.75 price target on the stock in a research note on Monday, March 20th. FBR & Co downgraded shares of Galena Biopharma from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $11.00 to $4.00 in a research note on Monday, February 6th. Finally, Maxim Group downgraded shares of Galena Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, February 2nd. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $2.93.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Galena Biopharma Inc (GALE) to Post -$0.15 EPS” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/05/25/zacks-brokerages-anticipate-galena-biopharma-inc-gale-to-post-0-15-eps.html.

Galena Biopharma (NASDAQ:GALE) opened at 0.5926 on Thursday. Galena Biopharma has a 52 week low of $0.52 and a 52 week high of $49.80. The company’s 50 day moving average is $0.58 and its 200-day moving average is $1.32. The firm’s market cap is $22.18 million.

An institutional investor recently bought a new position in Galena Biopharma stock. Renaissance Technologies LLC bought a new stake in Galena Biopharma Inc (NASDAQ:GALE) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,600,275 shares of the biotechnology company’s stock, valued at approximately $976,000. Renaissance Technologies LLC owned approximately 4.45% of Galena Biopharma at the end of the most recent reporting period.

Galena Biopharma Company Profile

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

12 Month Chart for NASDAQ:GALE

Get a free copy of the Zacks research report on Galena Biopharma (GALE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galena Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.